Amplia has received a grant through Innovation Connections to support a research collaboration with CSIRO to develop formulations of its Focal Adhesion Kinase (FAK) inhibitors that could be applied topically to wounds and burns to aid healing and reduce scarring.
This is an exciting new field of scientific discovery - FAK is believed to be involved in the formation of scar tissue, with implications for wound healing in patients. Scar tissue is the result of another form of aberrant fibrosis and as such FAK inhibitors may have utility in this field.
The global wound healing market is estimated to be in excess US$20b and the market for scar treatments is of similar size.
While Amplia’s primary focus continues to be on its ACCENT trial of AMP945 in pancreatic cancer patients, the science that underpins FAK inhibitors in this new field is definitely worth examining closely.
See ASX release here: chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02668674-2A1450692?access_token=83ff96335c2d45a094df02a206a39ff4
firstname.lastname@example.orgAn initiative ofBioMelbourne NetworkLevel 4, ANZAC House4 Collins StreetMelbourne Vic 3000
Wilam means home in the Woi-wurrung language of the Wurundjeri People of the Kulin Nation, the Traditional Owners of the lands on which we are based.We extend our respect to all Aboriginal and Torres Strait Islander peoples throughout Australia. We pay our respects to their cultures, knowledge, and communities, to the Elders, past, present, and emerging.